CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia.
CTLA4Ig
DLI
Haploidentical
Immunotherapy
NK cell
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
22
09
2018
accepted:
27
12
2018
pubmed:
6
1
2019
medline:
8
2
2020
entrez:
6
1
2019
Statut:
ppublish
Résumé
CTLA4Ig attenuates T cell activation by co-stimulation blockade, but natural killer (NK) cells are not only resistant to CTLA4Ig, they also may demonstrate better antileukemia effect in the presence of CTLA4Ig. To explore this phenomenon we used sequential CTLA4Ig primed donor lymphocyte infusion (DLI) after post-transplant cyclophosphamide-based haploidentical transplantation. Thirty patients (CTLA4Ig-DLI group) with advanced leukemia received CTLA4Ig on day -1 and subsequently on days +7, +21, and +35, followed 12hours later by DLI of 1 to 10 × 10
Identifiants
pubmed: 30610925
pii: S1083-8791(18)31769-5
doi: 10.1016/j.bbmt.2018.12.836
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-682Informations de copyright
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.